2 days ago
1
Hailshadow/iStock via Getty Images
Ultragenyx Pharmaceutical (NASDAQ:RARE) fell ~23%, and Mereo BioPharma (NASDAQ:MREO), its partner for bone disorder therapy UX143 (setrusumab), lost ~36% in the premarket on Thursday after the companies updated on a late-stage program for the drug.
The antibody therapy is currently
English (US) ·